OIS Podcast | Ophthalmology's leading Podcast

Nanoscope Therapeutics COO Paul Hallen discusses Mogenry's bipolar cell bypass mechanism and launch readiness.

6 min Listen to the original
Gene TherapyOphthalmologyRetinitis PigmentosaBiotechClinical TrialsCommercializationCold ChainReimbursement

Summary

Paul Hallen, COO of Nanoscope Therapeutics, joins the OIS Podcast to discuss Mogenry, a gene therapy that bypasses damaged photoreceptors by using an AAV vector to express opsins in intact bipolar cells. He notes that peak vision improvement occurs over five to six months, with sustained improvement of up to three lines of vision over three years. Hallen highlights the therapy's safety profile, citing zero Serious Adverse Events in the Remains study, and its applicability across 300+ genetic variants of Retinitis Pigmentosa as well as Stargardt's and Dry AMD. He emphasizes the operational complexity of the deep cold chain required for delivery and the importance of pre-secured reimbursement approvals for a successful launch.

Key takeaways

  1. 1
    Peak vision improvement takes five to six months post-injection, indicating a delayed therapeutic effect.

    Unidentified speaker (speaker_1) · 2:20

  2. 2
    It goes through a deep cold chain process from us all the way to the customer. Uh so it's very complicated and it takes a lot of partners and a lot, a lot of great internal talent as well.

    Unidentified speaker (speaker_1) · 3:38

Episode sections

  1. 0:03 – 1:35

    Introduction and Speaker Background

    Host Carey Powers introduces guest Paul Hallen, COO of Nanoscope Therapeutics, at OIS Retina in Montreal. Hallen discusses his transition from 37 years at Alcon to Nanoscope, citing a TED talk by Ed Boynton as inspiration.

  2. 1:35 – 2:29

    Mechanism of Action and Cellular Process

    Hallen explains that Nanoscope's therapy bypasses damaged photoreceptors by hijacking intact bipolar cells. The AAV vector enters bipolar cells, expressing opsins to sense light, with peak vision improvement occurring over five to six months.

  3. 2:29 – 3:08

    Treatment Durability and Comparison to Surgery

    The therapy, Mogenry, is a single intravitreal injection providing sustained improvement of up to three lines of vision over three years. Hallen contrasts this favorably against surgical vitrectomy procedures.

  4. 3:08 – 3:56

    Commercial Readiness and Cold Chain Logistics

    Hallen defines readiness as operational capability, including manufacturing consistency and serialization. He highlights the complexity of the deep cold chain required to deliver the therapy from manufacturer to customer.

  5. 3:56 – 4:51

    Safety, Efficacy, and Disease Agnostic Nature

    Data from the Remains study shows zero Serious Adverse Events (SAEs) and efficacy across 300+ genetic variants of Retinitis Pigmentosa (RP). The therapy is also disease-agnostic, applicable to Stargardt's and Dry AMD.

  6. 4:51 – 5:23

    Day One Launch Process and Reimbursement

    Upon approval, specialists will receive pre-trained support and pre-approved reimbursement for patients. The administration is a simple injection following cold storage handling.

  7. 5:23 – 6:17

    Operational Challenges and Conclusion

    Hallen describes the remaining path to launch as highly complex with many operational hurdles, requiring rigorous double-checking before market entry. The episode concludes with standard podcast sign-offs.

Claims worth verifying

Paul Hallen spent 37 years developing and optimizing retina equipment for surgery at Alcon.

Unidentified speaker (speaker_1) ·0:50

How to verify: Paul Hallen's LinkedIn profile and Alcon corporate press releases regarding his tenure. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Nanoscope's lead asset, Mogenry, is moving through a rolling BLA submission with the FDA.

Unidentified speaker (speaker_0) ·0:23

How to verify: FDA Orphan Drug Database or Nanoscope Therapeutics investor relations page for BLA status updates. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

The therapy hijacks bipolar cells to turn them into de facto photoreceptors if the bipolar cell layer is intact.

Unidentified speaker (speaker_1) ·1:51

How to verify: Nanoscope Therapeutics scientific publications or white papers detailing the mechanism of action for Mogenry. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Peak vision improvement is reached five to six months after injection.

Unidentified speaker (UNKNOWN) ·2:20

How to verify: Clinical trial data from the Remains study published in peer-reviewed journals or presented at ophthalmology conferences. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Three-year data shows sustained visual improvements of up to three lines of vision average in Retinitis Pigmentosa and Macular Telangiectasia.

Unidentified speaker (speaker_1) ·2:38

How to verify: Remains study results published in medical journals or presented at the OIS Retina conference. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

The therapy is delivered as a single intravitreal injection.

Unidentified speaker (UNKNOWN) ·2:29

How to verify: FDA Investigational New Drug (IND) application or Nanoscope Therapeutics clinical trial protocols. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

There are zero Serious Adverse Events (SAEs) to date.

Unidentified speaker (speaker_1) ·4:10

How to verify: Safety data tables in the Remains study publication or FDA briefing documents. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

There are approximately 300 genetic variants of Retinitis Pigmentosa (RP).

Unidentified speaker (UNKNOWN) ·4:27

How to verify: Genetic databases such as OMIM (Online Mendelian Inheritance in Man) or RetNet. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

The therapy is applicable to Stargardt's disease and Dry AMD.

Unidentified speaker (UNKNOWN) ·4:27

How to verify: Nanoscope Therapeutics clinical trial indications or press releases regarding disease-agnostic claims. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Nanoscope has pre-approved reimbursement for patients.

Unidentified speaker (speaker_1) ·4:58

How to verify: Nanoscope Therapeutics investor presentations or press releases detailing commercial readiness and payer negotiations. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify the Remains study data for Serious Adverse Events and efficacy metrics across genetic variants.
  • Confirm the specific AAV vector serotype and opsin expression levels used in Mogenry.
  • Assess the logistics and cost implications of the deep cold chain distribution network.
  • Review pre-secured reimbursement agreements with major payers for Stargardt's and Dry AMD indications.
  • Check for any ongoing or completed clinical trials comparing Mogenry to standard of care treatments.
  • Investigate Nanoscope Therapeutics' manufacturing capacity and serialization capabilities.
  • Look for independent expert commentary on the durability of vision improvement over the three-year period.
  • Verify the regulatory status of Mogenry in key markets (FDA, EMA) and any pending advisory committee meetings.
Full transcriptexpand
0:03
Unidentified speaker (speaker_0): Welcome to ION Innovation, brought to you by the OAS Podcast. I'm your host, Carrie Powers, and we are here at OAS Retina in Montreal talking to the leaders who are on the forefront of what is next in retina care. My guest today is Paul Howland, the new chief operating officer for nanoscope
0:23
Unidentified speaker (speaker_0): therapeutics. Paul spent decades leading the global retina franchise. for Elcon before joining Nanoscope earlier this year, stepping into the role at a pivotal moment for the company where Nanoscope's lead asset, Mojanry, is now moving through a rolling BLA submission with the FDA. So, Paul, thanks so much for joining us. It's
0:42
Unidentified speaker (speaker_1): my pleasure.
0:43
Unidentified speaker (speaker_0): And congrats on the new role.
0:44
Unidentified speaker (speaker_1): Thank you very much.
0:45
Unidentified speaker (speaker_0): Very exciting. So you're just a few months into the role. So what drew you to Nanoscope? Yeah.
0:50
Unidentified speaker (speaker_1): about four months into the role. And uh essentially it spent the last 37 years developing optimizing retina equipment for surgery. And I think we got to a point with the last console that we made, uh Unity VCS, that we kind of achieved everything um that I could imagine. And so it was time to do something else. And uh
1:10
Unidentified speaker (speaker_1): I had watched a uh TED talk by Ed Boynton about two what 11 years 15 years ago actually. And um he basically predicted nanoscope.
1:23
Unidentified speaker (speaker_0): Wow, that's a phenomenal story. Bringing it full circle with your background as
1:28
Unidentified speaker (UNKNOWN): well.
1:28
Unidentified speaker (speaker_0): Very exciting. So most gene therapies target just one specific mutation.
1:35
Unidentified speaker (speaker_0): So how would you explain the difference to someone outside the field?
1:38
Unidentified speaker (UNKNOWN): Yeah,
1:39
Unidentified speaker (speaker_1): it's number one, it's very difficult to change the genetics, but we basically have a bypass. So if your photoreceptors are damaged or dying, but you have an intact bipolar cell layer,
1:51
Unidentified speaker (speaker_1): then we can uh hijack that basically and turn those into de facto photoreceptors.
1:57
Unidentified speaker (UNKNOWN): So
1:57
Unidentified speaker (speaker_0): walk us through what happens at the cellular level when a patient receives the injection.
2:01
Unidentified speaker (speaker_1): It's very interesting. The AAV vector diffuses its way down through the vitreous, through the inner retina, and it's preferential to enter the bipolar cells. And then over a matter of weeks,
2:13
Unidentified speaker (UNKNOWN): um
2:13
Unidentified speaker (speaker_1): the gene opsin then expresses itself into the cell membrane and then begins
2:20
Unidentified speaker (UNKNOWN): to
2:20
Unidentified speaker (speaker_1): sense ambient light. And then over the course of many months, the patient patients starts start seeing better and better. And it actually takes five, six months before they reach their peak vision.
2:29
Unidentified speaker (UNKNOWN): So
2:29
Unidentified speaker (speaker_0): Mogenery is delivered as a single intravitreal injection. What does that mean for patients compared to therapies that require ongoing treatment?
2:38
Unidentified speaker (speaker_1): Well, so far through three years, uh we've had sustained visual improvements up to three lines of vision average in retinitis pigmentosa. Mentosa. So we hope it's a one one-and-done. and done. We're prepared if we need to do future injections.
2:52
Unidentified speaker (speaker_1): that are not virally based, but it's pretty amazing. So it may be one and done. And the simple intravitral injection is a lot better than going to the operating room and having your vitreous removed and inserting fluid underneath your retina. So it's it's a huge advantage.
3:08
Unidentified speaker (UNKNOWN): So
3:08
Unidentified speaker (speaker_0): you spent years building Alcon's retina franchise. What does commercial readiness mean for a therapy like Mojango? Mojenry, one that doesn't fit the mold for a typical drug or device launch?
3:19
Unidentified speaker (speaker_1): Yeah, I think it actually, some people will take commercial and they'll lean on those things associated with that. It's really operational readiness. We have more than six partners that are experts in gene therapy, various basic steps along the way. But essentially it's having everything ready. Uh So, you know, the product, can we manufacture it?
3:38
Unidentified speaker (speaker_1): consistently? Can we package it, serialize it? It goes through a deep cold chain process from us all the way to the customer. Uh so it's very complicated and it takes a lot of partners and a lot, a lot of great internal talent as well.
3:56
Unidentified speaker (speaker_0): So there's now multi-year data behind Mojanry, Mojangri, three-year durability results from the Remains study. Um from a commercial readiness standpoint, how much does that data matter for getting physicians comfortable with adopting a brand new therapy?
4:10
Unidentified speaker (speaker_1): Yeah, I think it it's fundamental. So um it needs to work, it needs to be efficacious, it needs to be safe. So we got the three lines, and we also um have zero SAEs to date. So it's very safe uh as far as we've gone. And then on top of that.
4:27
Unidentified speaker (UNKNOWN): one
4:27
Unidentified speaker (speaker_1): of the unique features is that gene agnostic disease agnostic. So in RP, there's like 300 variants. It doesn't matter. It should work in all those. And also it also applies to the disease. If you've lost your photoreceptors in Stargards or in Dry AMD, we can replace that function as well. So uh then beyond
4:47
Unidentified speaker (speaker_1): that the simple intravitral injections is a bonus.
4:50
Unidentified speaker (UNKNOWN): So
4:51
Unidentified speaker (speaker_0): if Mojri is approved, what does day one look like for a retina specialist who wants to offer it to their patients?
4:58
Unidentified speaker (speaker_1): Yeah, I think that if you kind of walk through the process, the drug would be delivered in cold storage as we uh discussed. They would put that away. We've already pre-trained and rehearsed with them for a first patient. We have a patient that also um is pre-approved for the reimbursement. so all the reimbursement work has been done by us. After that,
5:18
Unidentified speaker (speaker_1): it's very simple. It's a simple intravital injection and their improvement process initiates.
5:23
Unidentified speaker (speaker_0): So last question, Paul. What's the biggest operational challenge left between where you are now and getting this into the hands of patients?
5:32
Unidentified speaker (speaker_1): There isn't one. There's a hundred. And
5:37
Unidentified speaker (UNKNOWN): it's
5:37
Unidentified speaker (speaker_1): very complex, but I kind of like that.
5:40
Unidentified speaker (UNKNOWN): Uh
5:40
Unidentified speaker (speaker_1): but uh you know it's just making sure that we've got everything done, double checked, and and ready to launch.
5:47
Unidentified speaker (UNKNOWN): Very
5:47
Unidentified speaker (speaker_0): good. Well, Paul, thanks so much for the update. Uh for our viewers and listeners on Logenery. I think the the entire community is excited about getting this into market.
5:56
Unidentified speaker (speaker_1): Thank you.
5:57
Unidentified speaker (speaker_0): Thanks so much for joining us on ION Innovation, and we'll be coming to you throughout the day or with more. updates from OIS Retina in Montreal. Subscribe wherever you get your podcasts, or if you'd like to watch our smiling faces on the video version, join us over on YouTube.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights